Rigenera® Device
Patented medical device for mechanical disaggregation of autologous tissue biopsies.
AMT® Triad
Progenitor cells, Human Smart Exosomes and extracellular matrix extracted in one closed process.
Micrografting
Immediate injection of the solution into affected scalp zones with no delay and no manipulation.
Mechanism & Scientific Rationale
Androgenetic alopecia is characterized by progressive follicular miniaturization driven by DHT-mediated signaling at the dermal papilla. The AMT® approach aims to restore the follicular niche microenvironment by replenishing progenitor cells and paracrine mediators.
The mastoid area is biologically DHT-insensitive, providing a reliable source of healthy tissue. The mechanical disaggregation protocol preserves cell viability, exosome integrity, and extracellular matrix architecture.
Human Smart Exosomes within the AMT® triad carry tissue-specific bioactive cargo including growth factors, microRNAs, and signaling proteins that help modulate inflammation, stimulate follicular stem cell activity, and promote anagen re-entry.
Device & System Differentiators
Only Patented AMT® Platform
The only system with CE-marked autologous micrografting and no regulatory alternative.
No Biological Manipulation
Fully mechanical process with no enzymes, no culture, no expansion, and no cryopreservation required.
Tissue-Specific Exosomes
Autologous exosomes matched to the patient's own biology, not pooled donors or cell lines.
30-Minute Full Procedure
From biopsy to injection in a single session with no laboratory downtime.
70 Billion Exosomes Quantified
Scientifically validated exosome yield per treatment, first in the market to quantify this.
Protocol Overview
Complete in-office procedure with no lab required and no pre-processing downtime.
1
Evaluate diagnosis, scalp condition, pattern of loss, and clinical suitability before planning the procedure.
Patient Assessment
2
Small autologous tissue samples are collected from the mastoid area using the prescribed protocol.
Biopsy Collection
3
Mechanical
The Rigenera device processes the tissue mechanically to preserve cells, exosomes, and extracellular matrix.
Mechanical
Disaggregation
4
Target areas are prepared for precise placement of the autologous regenerative solution.
Scalp Preparation
5
AMT®
The prepared micrograft solution is immediately injected into affected scalp zones in the same session.
AMT®
Injection
6
No dressing required. The patient is discharged immediately with advice on expected mild scalp sensitivity for 24-48 hours.
Post-procedure
Candidate Selection
Who Is a
Who Is a
Good Candidate?
-
Androgenetic alopecia (AGA), male or female pattern.
-
Preference for an autologous, minimally invasive approach.
-
Patients seeking adjunctive therapy to pharmacological treatment.
-
Post-transplant scalp maintenance and follicular support.
-
Early to moderate thinning with preserved follicular units.
-
Patients suitable for periodic in-office regenerative maintenance.
Contraindications
When Not
When Not
to Treat
-
Active scalp infections including bacterial, fungal, or viral conditions.
-
Autoimmune alopecias such as alopecia areata, totalis, or universalis.
-
Scarring alopecias including lichen planopilaris and frontal fibrosing alopecia.
-
Active systemic inflammatory disease or uncontrolled comorbidities.
-
Pregnancy or breastfeeding.
-
Diffuse unpatterned alopecia (DUPA) as a relative contraindication.
Frequently Asked Questions
No. The AMT suspension is obtained through controlled mechanical disaggregation of the patient’s own tissue biopsy. Once prepared, the suspension is injected gently into the scalp at 0.1 mL per cm² with no further manipulation required.
AMT is typically performed once a year. Your physician will recommend follow-up timing based on your individual response, with many patients starting to see new hair growth around the 3-month mark.
The AMT suspension should be used immediately after preparation. The procedure is completed in a single ~30-minute in-clinic session, and the suspension is injected the same day.
Yes. AMT works well alongside:
Hair transplant (before, during, or after)
Activa Hair™ topical (between AMT sessions to sustain results)
Pharmacological treatments (finasteride/minoxidil) to stabilize progression
PRP or other adjuvants (with a 3–6 month rest period between procedures)
Yes. Proper training on the Rigeneracons/EVO device, biopsy extraction technique, cell isolation, and injection protocol is essential. Your distributor provides comprehensive training and support.
AMT counteracts DHT-driven mechanisms and supports the follicular microenvironment, but AGA remains chronic. If results plateau, your physician may recommend:
A follow-up AMT session (typically after 12 months)
Combination with complementary treatments (topicals, pharmacological therapy)
Evaluation of adherence to post-procedure care guidelines
Results vary by individual. Clinical studies report measurable improvements in hair density and thickness in most patients.
